Page 289 | ASweetLife

Glucose Test Strips Recalled: Risk of False Low Blood Glucose Results

Abbott Diabetes Care and the FDA have recalled 359 different lots of glucose test strips marketed under the following brand names: Precision Xceed Pro, Precision Xtra, Medisense Optium, Optium, OptiumEZ and ReliOn Ultima. The problem with these strips relates to a defect that inhibits sufficient absorption of blood into the test strip. Strips exposed to warm weather or prolonged storage may be more likely to provide a false result...

Addicted to Cereal

Like many people, I grew up eating cereal for breakfast. It seemed like a good, healthy thing to eat (as long as it wasn’t a “real sugar cereal” like…

Increasing Beta Cell Supply: An Interview With Professor Shimon Efrat

We have shown that beta cells from adult human islets can be made to multiply in tissue culture, but during this process they lose their ability to produce insulin...

Teva To Market a Generic Version of ACTOS in 2012

Takeda Pharmaceutical Company Limited has granted Teva Pharmaceutical Industries Ltd. a license to market a generic version of ACTOS® in the U.S. beginning on August 17, 2012, and a generic version of ACTOplus met® beginning December 14, 2012. The license was granted following an agreement to settle patent litigation related to Teva's generic versions of Takeda's ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl) in the United States...

Novo Nordisk to Develop Oral Insulin

Novo Nordisk has announced the signing of an exclusive Development and Licence Agreement with Emisphere Technologies, Inc. to develop and commercialize oral formulations ofNovo Nordisk’s insulins. This is the second license agreement between the two companies. The first agreement for the development of oral formulations of GLP-1 receptor agonists was signed...

Sanofi-aventis Acquires Next Generation Drug Delivery Technology for Diabetes Treatment

Sanofi-aventis announced it has signed a global licensing and patent transfer agreement with Ascendis Pharma (Ascendis) on Ascendis’ proprietary TransCon Linker and Hydrogel carrier technology, which allows for a drug compound to be released in the body in a precise, time-controlled fashion, creating a long-acting effect...

Amylin Submits Initial Sections of Rolling Biologics License Application for Metreleptin

Amylin Pharmaceuticals, Inc. announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy. Consistent with the severity and rare nature of the disorder...